ILMN Stock Analysis: Illumina | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 39.950m USD | 12M Return: 188.1% | US4523271090 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 838M
EPS Trend: 95.5%
Qual. Beats: 0
Rev. Trend: -45.6%
Qual. Beats: 4
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Illumina, Inc. is a leading provider of sequencing- and array-based solutions for genetic and genomic analysis, operating globally across the Americas, Europe, Greater China, Asia Pacific, the Middle East, and Africa. The company sells instruments and consumables-including reagents, flow cells, and library preparation kits-along with whole-genome and targeted resequencing kits. It also offers services such as whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support.
Illuminas customer base spans genomic research centers, academic institutions, government laboratories, hospitals, and pharmaceutical, biotechnology, molecular diagnostic, and consumer genomics companies. Products are sold both directly and through life-science distributors. The company follows a classic razor-and-blade business model common to the Life Sciences Tools & Services sub-industry, generating recurring revenue from consumables tied to its installed base of sequencing instruments.
Illumina maintains strategic collaborations with Labcorp Holdings (oncology treatment development), Integrated DNA Technologies (integrated NGS somatic oncology workflows), and the Center for Data-Driven Discovery in Biomedicine (pediatric cancer and rare disease research). Founded in 1998 and headquartered in San Diego, California, Illumina is a large-cap U.S. health care company listed on NASDAQ under the ticker ILMN since its 2000 IPO.
- Greater China sequencing demand pressured by export controls
- GRAIL divestiture unlocks capital return and margin recovery
- NovaSeq X placements face rising low-cost sequencer competition
| Net Income: 825.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA -2.82 > 1.0 |
| NWC/Revenue: 27.95% < 20% (prev 27.56%; Δ 0.40% < -1%) |
| CFO/TA 0.16 > 3% & CFO 1.09b > Net Income 825.0m |
| Net Debt (1.91b) to EBITDA (1.36b): 1.40 < 3 |
| Current Ratio: 1.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (153.0m) vs 12m ago -2.55% < -2% |
| Gross Margin: 66.79% > 18% (prev 67.14%; Δ -0.35% > 0.5%) |
| Asset Turnover: 70.55% > 50% (prev 70.35%; Δ 0.20% > 0%) |
| Interest Coverage Ratio: 10.79 > 6 (EBIT TTM 1.09b / Interest Expense TTM 101.0m) |
| A: 0.19 (Total Current Assets 2.83b - Total Current Liabilities 1.58b) / Total Assets 6.65b |
| B: -0.01 (Retained Earnings -51.0m / Total Assets 6.65b) |
| C: 0.17 (EBIT TTM 1.09b / Avg Total Assets 6.37b) |
| D: 0.74 (Book Value of Equity 2.84b / Total Liabilities 3.81b) |
| Altman-Z'' = 3.15 = A |
| DSRI: 1.02 (Receivables 764.0m/716.0m, Revenue 4.49b/4.28b) |
| GMI: 1.01 (GM 67.14% / 66.79%) |
| AQI: 1.09 (AQ_t 0.41 / AQ_t-1 0.38) |
| SGI: 1.05 (Revenue 4.49b / 4.28b) |
| TATA: -0.04 (NI 825.0m - CFO 1.09b) / TA 6.65b) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of October 16, 2026, the stock is trading at USD 267.93 with a total of 2,988,915 shares traded. Over the past week, the price has changed by +1.27%, over one month by +20.53%, over three months by +43.16% and over the past year by +188.10%.
Current recommended Stop Loss: 250.90 (which is 6.4% or 1.3 ATR below the current price).
Illumina has received a consensus analysts rating of 3.57. Therefore, it is recommended to hold ILMN.
- StrongBuy: 7
- Buy: 4
- Hold: 6
- Sell: 2
- StrongSell: 2
| Analysts Target Price | 232.2 | -13.4% |
P/E Trailing = 49.3601
P/E Forward = 40.3226
P/S = 8.8896
P/B = 13.1665
P/EG = 3.0533
Revenue TTM = 4.49b USD
EBIT TTM = 1.09b USD
EBITDA TTM = 1.36b USD
Long Term Debt = 1.49b USD (from longTermDebt, last fiscal year)
Short Term Debt = 582.0m USD (from shortTermDebt, last quarter)
Debt = 3.08b USD (from shortLongTermDebtTotal, last quarter) + Leases 555.0m
Net Debt = 1.91b USD (calculated: Debt 3.08b - CCE 1.17b)
Enterprise Value = 41.9b USD (40.0b + Debt 3.08b - CCE 1.17b)
Interest Coverage Ratio = 10.79 (Ebit TTM 1.09b / Interest Expense TTM 101.0m)
EV/FCF = 44.58x (Enterprise Value 41.9b / FCF TTM 939.0m)
FCF Yield = 2.24% (FCF TTM 939.0m / Enterprise Value 41.9b)
FCF Margin = 20.90% (FCF TTM 939.0m / Revenue TTM 4.49b)
Net Margin = 18.36% (Net Income TTM 825.0m / Revenue TTM 4.49b)
Gross Margin = 66.79% ((Revenue TTM 4.49b - Cost of Revenue TTM 1.49b) / Revenue TTM)
Gross Margin QoQ = 66.44% (prev 66.09%)
Tobins Q-Ratio = 6.30 (Enterprise Value 41.9b / Total Assets 6.65b)
Interest Expense / Debt = 3.28% (Interest Expense 101.0m / Debt 3.08b)
Taxrate = 18.72% (190.0m / 1.01b)
NOPAT = 886.0m (EBIT 1.09b * (1 - 18.72%))
Current Ratio = 1.80 (Total Current Assets 2.83b / Total Current Liabilities 1.58b)
Debt / Equity = 1.09 (Debt 3.08b / totalStockholderEquity, last quarter 2.84b)
Debt / EBITDA = 1.40 (Net Debt 1.91b / EBITDA 1.36b)
Debt / FCF = 2.04 (Net Debt 1.91b / FCF TTM 939.0m)
Total Stockholder Equity = 2.65b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.95% (Net Income 825.0m / Total Assets 6.65b)
RoE = 31.08% (Net Income TTM 825.0m / Total Stockholder Equity 2.65b)
RoCE = 26.30% (EBIT 1.09b / Capital Employed (Equity 2.65b + L.T.Debt 1.49b))
RoIC = 16.32% (NOPAT 886.0m / Invested Capital 5.43b)
WACC = 9.10% (E(40.0b)/V(43.0b) * Re(9.60%) + D(3.08b)/V(43.0b) * Rd(3.28%) * (1-Tc(0.19)))
Discount Rate = 9.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -89.62 | Cagr: -1.70%
[DCF] Terminal Value 71.43% ; FCFF base≈975.8m ; Y1≈906.4m ; Y5≈821.7m
[DCF] Fair Price = 63.81 (EV 11.5b - Net Debt 1.91b = Equity 9.64b / Shares 151.0m; r=9.10% [WACC]; 5y FCF grow -8.92% → 2.50% )
EPS Correlation: 95.50 | EPS CAGR: 125.1% | SUE: 0.32 | # QB: 0
Revenue Correlation: -45.62 | Revenue CAGR: -0.91% | SUE: 1.93 | # QB: 4
EPS current Quarter (2026-09-30): EPS=1.36 | Chg30d=+0.07% | Revisions=-12% | Analysts=19
EPS current Year (2026-12-31): EPS=5.36 | Chg30d=+0.04% | Revisions=+0% | GrowthEPS=+10.7% | GrowthRev=+6.5%
EPS next Year (2027-12-31): EPS=6.12 | Chg30d=+0.33% | Revisions=+29% | GrowthEPS=+14.2% | GrowthRev=+6.5%
[Analyst] Revisions Ratio: +0% (up=10, down=10)